BV8 nucleic acids and polypeptides with mitogenic activity

Details BV8 nucleic acids and polypeptides with mitogenic activity BV8 nucleic acids and polypeptides with mitogenic activity

2006-09-29

2010-10-12

Rawlings, Stephen L (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07811984

ABSTRACT:
The present invention provides methods of using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival. Also provided herein are methods of screening for modulators of Bv8 activity. Furthermore, methods of treatment using Bv8 polypeptides are provided.

REFERENCES:
patent: 4109496 (1978-08-01), Allemann et al.
patent: 4419446 (1983-12-01), Howley et al.
patent: 4601978 (1986-07-01), Karin
patent: 5010182 (1991-04-01), Brake et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5364934 (1994-11-01), Drayna et al.
patent: 5561053 (1996-10-01), Crowley
patent: 5605793 (1997-02-01), Stemmer
patent: 5837458 (1998-11-01), Minshull et al.
patent: 5976782 (1999-11-01), Parish et al.
patent: 7060278 (2006-06-01), Ferrara et al.
patent: 2002/0172678 (2002-11-01), Ferrara et al.
patent: 0 307 247 (1989-03-01), None
patent: 0 362 179 (1990-04-01), None
patent: WO 90/13646 (1990-11-01), None
patent: WO 91/08291 (1991-06-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 98/10071 (1998-03-01), None
patent: WO 01/36465 (2001-05-01), None
patent: WO 02/00711 (2002-01-01), None
patent: WO 02/36625 (2002-05-01), None
patent: WO 2004/081229 (2004-09-01), None
Nor et al (Angio., 3:101-116, 1999).
Eming et al (Prog, Hist. Cyto., 42:115-170, 2007).
Jones (Pharmacogenomics Journal, 1:126-134, 2001).
Tosatto et al (Current Pharmaceutical Design, 12:2067-2086, 2006).
Skolnick et al. (Trends in Biotechnology 2000; 18: 34-39).
Guo et al. (Proc. Natl. Acad. Sci. USA. Jun. 22, 2004; 101 (25): 9205-9210).
Ferrara et al (Biochim. Biophys. Acta., 1654:69-78:2004).
Masuda et al (Biochem. Biophys. Res. Com., 293(1):396-402, 2002).
Thiboutot et al (J. Invest. Derm. 120:905-914, 2003).
Galiano et al (Am. J. Path., 164(6):1935-1947, 2004).
Aird, W. et al., 1997,The Journal of Cell Biology, 138(5):1117-1124 “Vascular Bed-specific Expression of an Endothelial Cell Gene is Programmed by the Tissue Microenvironment”.
Aravind, L. et al., 1998,Current Biology, 8(14):R477-R478 “A colipase fold in the carboxy-terminal domain of the Wnt antagonists—the Dickkopfs”.
Aruffo, A. et al., 1990,Cell, 61:1303-1313 “CD44 is the Principal Cell Surface Receptor for Hyaluronate”.
Ashkenazi, A. et al., 1993,Intern. Rev. Immunol., 10:219-227 “Immunoadhesins”.
Ashkenazi, A. et al., 1991,Proc. Natl. Acad. Sci. USA, 88:10535-10539 “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin”.
Bianchi, M. et al., 1987,Curr. Genet., 12:185-192 “Transformation of the yeastKluyveromyces lactisby new vectors derived from the 1.6 μm circular plasmid pKDI”.
Bowie et al., 1990,Science, 247″ 1306-1310 “Deciphering the Message in Protein Sequences: Tolerance to Amino Substitutions”.
Burgess et al., 1990,Journal of Cell Biology, 111:2129-2138 “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”.
Carmeliet, P., 2000,Nature Medicine, 6(3):389-395 “Mechanisms of angiogenesis and arteriogenesis”.
Carter, P. et al., 1985,Nucleic Acids Research, 13(12):4431-4443 “Improved oligonucleotide site-directed mutagenesis using M13 vectors”.
Carter, P. et al., 1992,Bio/Technology, 10:163-167 “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment”.
Chothia, C. et al., 1987,J. Mol. Biol., 196:901-917 “Canonical Structures for the Hypervariable Regions of Immunoglobulins”.
Cunningham, B. et al., 1989,Science, 244:1081-1085 “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”.
Dellian, M. et al., 1996,Amer. Journal of Pathology, 149(1):59-71 “Quantitation and Physiological Characterization of Angiogenic Vessels in Mice”.
Dietsch, M. et al., 1993,Journal of Immunological Methods, 162:123-132 “Bispecific receptor globulins, novel tools for the study of cellular interactions”.
Dzau, V. et al., 1993,Trends Biotechnol., 11:205-210 “Gene therapy for cardiovascular disease”.
Ferrara, N. et al., 1999,Nature Medicine, 5(12):1359-1364 “Clinical applications of angiogenic growth factors and their inhibitors”.
Fleer, R. et al., 1991,Bio/Technology, 9:968-975 “Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin byKluyveromycesYeasts”.
Gascoigne, N. et al., 1987,PNAS USA, 84:2936-2940 “Secretion of a chimeric T-cell receptor-immunoglobulin protein”.
Gautier et al., 1987,Nucleic Acids Research, 15(16):6625-6641 “DNA IV: α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding”.
Hoogenboom, H. et al., 1991,Molecular Immunology, 28(9).1027-1037 “Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins”.
Houghten, R. et al., 1991,Nature, 354:84-86 “Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery”.
Inoue, H. et al., 1987,FEBS Letters, 215(2):327-330 “Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H”.
Inoue, H. et al., 1987,Nucleic Acids Research, 15(15):6131-6148 “Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucieotides”.
Keck, P. et al., 1989,Science, 246:1309-1312 “Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF”.
Lam, K. et al., 1991,Nature, 354:82-84 “A new type of synthetic peptide library for identifying ligand-binding activity”.
Lazar et al., 1988,Molecular and Cellular Biology, 8:1247-1252 “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”.
LeCouter, J. et al., 2001,Nature, 412:877-884 “Identification of an angiogenic mitogen selective for endocrine gland endothelium”.
LeCouter, J. et al., 2003,PNAS, 100(5):2685-2690 “The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells”.
Leung, D. et al., 1989,Science, 246:1306-1309 “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen”.
Li, M. et al., 2001,Molecular Pharm., 59(4):692-698 “Identification of Two Prokineticin cDNAs: Recombinant Proteins Potently Contract Gastrointestinal Smooth Muscle”.
Lovell, D. et al., 2000,The New England Journal of Medicine, 342(11):763-769 “Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis”.
Maini, R. et al., 2000,Annu. Rev. Med., 51:207-229 “Anti-Cytokine Therapy for Rheumatoid Arthritis”.
Martin, S. et al., 1993,Journal of Virology, 67(6);3561-3568 “Efficient Neutralization and Disruption of Rhinovirus by Chimeric ICAM-I/Immunoglobulin Molecules”.
Mollay, C. et al., 1999,European Journal of Pharmacology, 374:189-196 “Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats”.
Platt, K. et al., 1994,The Journal of Biological Chemistry, 269(46):28558-28562 “Independent Regulation of Adipose Tissue-specificity and Obesity Response of the Adipsin Promoter in Transgenic Mice”.
Roberts, W. et al., 1998,Amer. Journal of Pathology, 153(4).1239-1248 “Host Microvasculature Influence on Tumor Vascular Morphology and Endothelial Gene Expression”.
Schweitz, H. et al., 1999,FEBS Letters, 461:183-188 “MIT1, a black mamba toxin with a new and highly potent activity on intestinal contraction”.
Siebenlist, U. et al., 1980,Cell, 20:269-281 “E. coliRNA Po

Affiliated with

Also associated with

Rating

BV8 nucleic acids and polypeptides with mitogenic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BV8 nucleic acids and polypeptides with mitogenic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BV8 nucleic acids and polypeptides with mitogenic activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4234299